The earliest studies in this series of experiments were performed using CBA mice that were immunosuppressed by 9 Gy whole-body radiation followed
During the past seven years we have coordinated a substantial programme of work on human tumour xenografts in immuno-suppressed mice. Much of the work was performed by clinical scientists who were released from clinical work to pursue a 1-2 year period of laboratory research; their names are listed below.* Each project concentrated upon a specific category of human cancer and led to its own specific conclusions. The purpose of this review is to bring together the therapeutic results of all these investigations and to present such general conclusions as can be drawn at the present time. These conclusions relate to two main questions: How satisfactory are human tumour xenografts for the evaluation of therapeutic response? and, To what extent do the results correspond with clinical experience in chemotherapy?
Immuno-suppressed mice
The earliest studies in this series of experiments were performed using CBA mice that were immunosuppressed by 9 Gy whole-body radiation followed immediately by a bone marrow graft (Kopper & Steel, 1975; Nowak et al., 1978) . The conventional procedure involved a graft of 5 x 106 nucleated marrow cells for reconstitution. Attempts to improve the receptivity of the mice to human tumour grafts indicated that some improvement was gained by reducing the size of the marrow graft to 2 x 105 cells and the mice survived equally well.
This procedure was not extensively used, however, because of the development of a simpler and probably more effective procedure.
It has been observed (Millar et al., 1978 ) that a number of cytotoxic drugs, given to mice a few days before whole-body radiation, increase the dose of radiation that can be tolerated. Increased radiation resistance is found both in the bone marrow and in the intestinal epithelium (Phelps & Blackett, 1979) . Among the various drugs that produce this effect, cytosine arabinoside (Ara C) is particularly useful, since it produces a good degree of protection and is well tolerated in single doses. The optimum procedure is to give 200mg kg-1 i.p. 48 h before irradiation. found that this allowed mice to tolerate 9 Gy whole-body irradiation without the need of a bone marrow graft; cell titration tests using cells from a xenografted human pancreatic carcinoma showed that mice prepared in this way were more receptive to grafting than marrow-reconstituted mice or even than nude mice. This procedure has been standard in this Department since that time.
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An important disadvantage of immunosuppressed mice is their tendency to recover the ability to reject human tumour cells during the few months following the procedure. found evidence for this by 6 weeks and it was subsequently found that raising the dose of wholebody irradiation increased the length of time for which the mice seemed highly receptive to about 3 months . Mice given radiation doses of 10 or Gy are more fragile than those given the standard dose and the oral administration of neomycin was necessary to reduce mortality.
Further attempts to improve the receptivity of mice to xenografts were reported by Bailey et al., (1980a) . In an effort to improve the take-rate of human breast tumours, which have widely been found difficult to graft, a variety of modifications were made to the immuno-suppression procedure. The age of the recipients at thymectomy was reduced from 4 to 3 weeks; the radiation dose was raised to lOGy, silica particles were injected i.p., oestrogen was administered, castrated male mice were used, the size of the tumour implant was increased, and nude mice were also used (these procedures were, of course, only tested singly). None of the techniques appeared to be an improvement over the standard procedure and the overall success rate (8 lines established from 80 patients) remained comparable with results reported by other investigators (Giovanella et al., 1976; Sebesteny et al., 1979; Rae-Venter & Reid, 1980 Pickard et al., (1975) ; Nowak et al., (1978) Stomach ca. Kopper & Steel (1975) , in 10 melanomas studied by Selby et al., (1980) , in 16 bronchial carcinomas studied by Shorthouse et al., (1980) , in 9 ovarian carcinomas and in 6 testicular teratomas . These investigations (which were performed by J. Mills and G. Casey) showed the occasional occurrence of a mouse mitotic figure which could arise from proliferating cells in the mouse stroma. No hybrid karyotypes were ever observed. There was, however, one case of a rapidly-growing tumour with an exclusively mouse karyotype appearing at the transplantation site of a teratoma xenograft which originally contained human chromosomes. Studies of LDH isoenzymes (Houghton & Taylor, 1978a) similarly confirmed the human origin of 6 colon carcinoma xenografts and all of 7 ovarian carcinoma lines were positive for human epithelial membrane antigen . Histological comparisons of the xenografts with their source tumours have been made in each type of tumour. In agreement with other investigators, our experience has been that the histological characteristics of the source tumours are usually well maintained by xenografts. Often the stromal elements are less pronounced and this may be associated with the more rapid growth of the tumours in the mouse than in man, and with the fact that the stromal tissue is of mouse origin (Warenius, 1980) . There was a frequent, but not universal tendency for the xenografts to be more anaplastic and pleomorphic than the source tumours. Houghton & Taylor (1978a) in colonic carcinomas and Shorthouse (1981) in bronchial carcinomas found that the pattern of production of epithelial mucins was well maintained. We have not observed the tendency towards increased differentiation reported by Sharkey et al., (1978) .
Tests for the presence of marker substances have been made in a number of disease categories. demonstrated positive assays for ectopic hormones in bronchial carcinomas: calcitonin (in 13% of xenografts), PHCG (in 13%), ACTH (in 78%) and CEA (in 56%).
The synthesis (as opposed to presence) of calcitonin, fHCG and ACTH was also demonstrated in proliferative cultures of a few cell lines and in 2 of these cases fHCG was also demonstrable in mouse plasma. Marker production in teratoma xenografts has been summarised by Raghaven et al., (1981) . Among 6 lines that were studied, 2 showed strong production of alphafoetoprotein (AFP) and in both cases the original patient specimen was also strongly positive for AFP. Similarly, a negative assay correlated with negative in the original specimen. The production of CEA by colon carcinoma xenografts was studied by Houghton & Taylor (1978a) . The protein was detected in all tested specimens of xenografts and high levels were associated with high levels in the clinical specimens. When affinity-purified antibodies to CEA were injected into mice bearing breast carcinoma xenografts (3 of the lines indicated in Table I ) specific localisation in tumour tissue was observed (Moshakis et al., 1981) .
Growth rates
The growth rates of xenografts were determined by caliper measurements on s.c. tumour implants. In most cases these were transformed into tumour volumes using the equation for the volume of an ellipsoid but in the case of the teratomas a calibration curve technique was used in which an empirically-determined relationship between the caliper measurements and the excised tumour weight was used to interpret subsequent caliper measurements (Steel, 1977, p.6) .
A summary of growth rate data is given in Table  II . The measurements were usually made on tumours in the size range 0.1-0.5 g (about 8-13 mm diameter). Growth rate often decreased with increasing tumour size, as is almost always found with syngeneic or xenografted tumours in the mouse (Steel, 1977) . It can be seen that in passage 0 (man-mouse) the average volume-doubling times range from 13.5 days in melanomas to 29.5 days in breast carcinomas. This difference is just significant at the 5% level. In the subsequent passages an increase in growth rate was found in all the tumour types, the overall average doubling time falling from 19.8 days to 11.1 days. Further acceleration sometimes occurred beyond passage 4. The most detailed study of growth acceleration through sequential passage was the work of Houghton & Taylor (1978b) who studied 6 colon carcinomas through up to 10 passages in male and female mice; the growth-rate changes were most marked during the first 3 passages. It will be seen in Table II Tables I and II reveals no correlation between the growth rate and success rate of these major xenograft categories (Figure 1 ). The only result that is suggestive of such a correlation is the low success rate and slow growth of the breast carcinomas. However, a positive correlation between growth rate and take-rate among bronchial carcinoma xenografts was found by Shorthouse (1981) . Selection in favour of rapidly growing cells is suggested by the clear tendency of xenografts to accelerate during passage in mice and by their tendency towards higher growth rate than is found in the patients. Clinical tumour growth rate data are available on few of the patients who donated tissues for the xenografts in this series (Shorthouse, 1981) but it is possible to compare the present data with other published data on human tumour growth rates (Steel, 1977;  (Table 1 ) indicate the proportion of tested patients from whom transplantable lines were obtained; growth rates ( In an idealised situation the results are as shown in Figure 2 . Growth of the treated tumours is retarded and they may even temporarily regress. The response curve for the treated tumours may be divided into 2 components: a declining component that represents the clearance of dead tissue and a regrowth component that initially is hidden but which eventually becomes dominant (see Steel, 1977, p. 249) . It is the second of these that reliably indicates the effects of treatment. The usual procedure, therefore is to choose a tumour volume that is a simple multiple of the tumour size at treatment and to measure the time taken for the treated and control tumours to reach this size. The greater the multiple, the more confident one can be that the treated tumours are actively regrowing beyond the treatment size. If, for simplicity, the end-point is taken at a relative volume of twice the treatment size then we can determine the time taken (T2, TI) for control and treated tumours to double their volume. The difference (T' -T2) equals the actual tumour growth delay.
If it is necessary to compare growth delay values between tumour types that differ widely in growth rate, the actual growth delay is clearly unsatisfactory. We have therefore followed the practice of calculating T'-T2 Specific Growth Delay = 2 2 T2 This could be described as the number of volume-doubling times by which growth is delayed and it allows comparisons to be made between tumours of different growth rate. Nevertheless, we recognise that even this manoeuvre is not ideal. There is good evidence (Stephens & Peacock, 1977; Steel & Stephens, 1978) that the tumour cells which survive cytotoxic treatment can repopulate with a doubling time that is considerably shorter than the doubling time of tumours at the time of treatment. This work also shows from one cytotoxic drug to another the rate of repopulation may differ. To interpret or to compare growth delay values one would like to divide them by the average doubling time of surviving clonogenic cells during the regrowth period up to TI but of course this is not known. The specific growth delay values as calculated must be regarded as the best approximation available to a standardised growth delay estimate.
The choice of drug dose is another difficult problem in xenograft chemotherapy studies, especially where the intention is to compare the effectiveness of a series of drugs. The procedure used throughout the present group of studies has been to employ each drug at its maximum tolerated dose in mice. The rationale behind this lies in the claim by Freireich et al., (1966) that a linear relationship exists between the LD1o doses of cytotoxic drugs in mice and their maximumtolerated levels in man. The necessary comparative pharmacokinetic data between man and mouse that might allow a more reliable choice of doses are not available. Figure 3 is a summary of growth delay data on 6 types of human cancer grown as xenografts. In each case the specific growth delay at an LD10 drug dose has been calculated. The actual drug doses used varied slightly from one study to another and the teratomas and small-cell lung tumours were so sensitive to treatment that in these cases to avoid response in enhancing tumour cure has been well demonstrated in the non-xenograft situation (Mantovani et al., 1979; Hengst et al., 1981) . In a number of chemotherapy studies on xenografts tumour cure was observed at drug doses that on the basis of lower dose studies would not have been expected to produce a very long growth delay. For instance, Kopper & Steel (1975) using a small-cell bronchial carcinoma in marrow-reconstituted mice found that cyclophosphamide gave a growth delay of 1.1 volume-doubling times at a dose of 120mgkg-1 and 3/8 tumours failed to regrow after a dose of 180mgkg-'. Such evidence suggests that clonogenic cell kill of only perhaps 2 decades (a surviving fraction of 1%) may achieve substantial tumour control when combined with an effective immune response. Whether this also leads to upward-bending dose-response curves at noncurative doses is not yet clear, for a survey of the literature reveals few well-defined dose-response curves for xenografts. Two studies from the present programme have examined tumour growth delay as a function of dose and in both cases the doseresponse curves were almost linear: small-cell lung tumours studied by and breast carcinoma xenografts studied by Bailey et al., (1980b) . However, a survey of published doseresponse data for the radiation treatment of xenografts shows that there has been a tendency towards upward curvature (see e.g. Rofstad & Brustad, (1978 , 1980 , who used melanomas and osteosarcomas in nude mice).
In face of the evident possibility of artefacts resulting from this phenomenon, we have also explored the use of a tumour growth inhibition endpoint: at some fixed time after treatment to measure the relative volume of treated and control tumours. This procedure has been widely used in experimental chemotherapy, including some studies on xenografts (Povlsen & Jacobsen, 1975; Shimosato et al., 1977) . The method has been criticised on the grounds that if the size determinations are made too early tumour regression will not yet be complete and the magnitude of response will be underestimated. But the method could be reliable provided there is evidence that at the time of measurement the treated tumours are actively regrowing. We have therefore re-analysed our data using this restriction, evaluating for each treated and control tumour the relative tumour size (V) at the end of the growth period compared with their size at the time of treatment and then calculating The FVR method is now in use for therapeutic studies on xenografts, for instance in teratomas which tend, especially after treatment, to become cystic. The opportunity to excise the tumours at one particular time and determine the cellular composition by weighing is an associated advantage over the growth delay method.
Comparative cell survival studies among xenografts The principal alternative to in situ methods of measuring therapeutic response in xenografts is to determine clonogenic cell survival. Tumour-bearing mice are treated, the tumours are excised within about a day, disaggregated into a single-cell suspension and the cells placed in an in vitro (or perhaps in vivo) environment in which their ability to form a colony can be evaluated (for review see Elkind & Whitmore, 1967; Steel, 1977) . A number of clonogenic assays have been developed for xenografted human tumours (Courtenay & Mills, 1978; Smith et al., 1976; Selby et al., 1980; Selby & Steel, 1982) . Plating efficiencies vary widely from very low levels in some tumours to -30% in favourable cases. Problems of tissue disaggregation are sometimes severe and at the present time only a minority of xenografted tumours are amenable to reliable clonogenic assay.
The great advantage of clonogenic cell survival as an end-point for xenograft studies is that by removing the treated and control cells into a common environment problems of host defence mechanisms are avoided. Other advantages of this approach are its sensitivity (often down to a surviving fraction of 10-3) and its ability to detect the presence or absence of resistant components within the tumour or a "shoulder" at low drug doses.
Chemotherapy studies of cell survival in the present research programme have included studies on pancreatic and bronchial carcinomas, melanomas, and a single survival curve for a colon carcinoma. Survival curves were in almost all cases indistinguishable from an exponential, with rare examples of a small shoulder. The only marked exception to this was in the response of two of the melanomas to DTIC, where the curves fell to a clear plateau at about 10-2 survival for drug doses in excess of 100mg kg-'. The steepness of the survival curves can therefore in most cases be expressed by the surviving fraction at the LD1o dose and these values (given as decades of cell kill) are summarised in Table IV . Values in excess of 3.0 indicate situations in which the survival at the LD1o dose was too low to measure, and linear extrapolation has been used.
Although data in Table IV do not include a wide variety of drugs or an extensive range of tumour types they do support the implications of the growth delay data that among a group of similar tumours the effectiveness of a particular drug can vary widely. It is even possible in some cases to quantify the variation: among the melanomas there is a 3-fold range of sensitivity to melphalan and a >5-fold range for MeCCNU. The two pancreatic tumour lines have very similar sensitivities to most drugs used but a > 5-fold difference for hexamethylmelamine . There is little opportunity to ask whether the cloning data also support the large differences between sensitive and resistant tumour types seen in Figure 3 , for only 2 data points are available for nominally chemosensitive disease: the small-cell carcinomas treated with the 3-drug combination MCC. These two were, however, very responsive.
Relation between cell survival and tumour growth delay
It is of some interest to enquire to what extent measurements of clonogenic cell survival correlate with growth delay measurements on the same drugs and tumours. The number of tumours in which this comparison can be made is not large and the data are summarised in Figure 5 . For points below a surviving fraction of 10-3 the survivals have been obtained by extrapolation up to the dose used in the growth delay determinations.
Among the sensitive tumours (i.e. those that give a specific growth delay greater than 1.0 or a surviving fraction below say 0.3) there is a general tendency for growth delay and log cell kill to increase together. There is by no means a tight relationship between these parameters, nor would one expect this. As shown in the B16 mouse melanoma by Stephens & Peacock (1977) the growth delay achieved for a fixed level of cell kill depends upon the drug used: for cyclophosphamide the growth delay was considerably greater than for CCNU and this difference was attributed to a faster rate of repopulation by surviving clonogenic cells after CCNU. ; the rest by in vitro assay (Courtenay & Mills, 1978 points the ratio of the post-to pre-treatment growth rates must range from about 2 to 10. If we assume that the scatter of t] chart is attributable to differences in acceleration in tumour cell repopulat during regrowth it is possible to calci this difference must be. To encompasi Evidence for individuality among human tumours The data presented in Figure 3 and Table IV Bailey et al. (1980b) . This was a similar study in breast carcinoma xenografts, employing 5 tumour lines challenged with 6 single agents and two drug combinations. By comparison with the colo-rectal tumours, this disease was more responsive to chemotherapy with an overall mean specific growth delay of 2.0. In this case there were significant differences among the tumour lines in their response to chemotherapy as well as significant differences among drugs in their effectiveness. Superimposed on these differences was an apparent degree of individuality in response to the most effective drugs: of the 5 tumour lines, one responded best to the CMF combination, 2 were best with melphalan and 2 best with the AV combination (see Legend to Figure 3 ). 3. Shorthouse et al., (1980ab; . In this extensive study on xenografts of bronchial carcinomas there was evidence that in addition to the marked differences between small-cell and non-small-cell tumours, those within a particular histopathological type also differed in drug sensitivity. There was no evidence for a difference in spectrum of drug response but some tumours were markedly more responsive than others. 4. Selby et al., (1980) . In this cell survival study on 5 melanoma xenograft lines measurable responses were only available to 3 drugs (melphalan, MeCCNU and DTIC). There was no evidence for individuality among these tumours and drugs. However, a parallel programme of in vitro chemosensitivity testing was carried out by Bateman et al., (1980) and a statistical analysis of the data yielded evidence for significant individuality in the response of 5 melanoma xenografts to melphalan, MeCCNU, cis-platinum and adriamycin. 5. Courtenay et al., (1982 However, the use of xenografts as models of particular human cancers is supported.
General conclusions
The body of data reviewed here comes from work on a wide range of types of human cancer, not only in respect of tissue origin but also of responsiveness to cytotoxic drug treatment. The drawbacks of in situ growth delay or cell survival studies have been indicated, but in spite of these there is clear evidence that the xenografts respond to drug treatment in a way that broadly would be expected on the basis of clinical experience. In terms of average response to the 3 agents that in each case were most effective, the 6 categories of disease for which results are shown in Figure 3 can be ranked (Table V) . This ranking is compared in Table V In addition to this plausible inter-type ranking there is also evidence that in any particular tumour type the drugs that do well clinically also rank high in xenografts: cyclophosphamide, CCNU and vincristine in small-cell lung cancer; bleomycin, and cis-platinum in testicular teratoma. However, there are also some surprising results, notably the marked effectiveness of procarbazine in small-cell tumours and the relatively poor performance of adriamycin in other than breast tumours. The ineffectiveness of VP16 in teratomas may well be associated with the known difficulty of ensuring high enough concentrations of this agent in a soluble form in mice; we suspect that as a result of this drug delivery problem the present data may under-rate the value of this agent. The relatively poor performance of methotrexate in breast and small-cell tumours is also remarkable, especially in view of the higher growth rate of the xenografts than of the corresponding disease in man. The breast xenografts received single dose treatment, the small-cell xenografts 3 doses over 24h. We are inclined to accept the xenograft data on methotrexate as possible evidence that the clinical activity of this drug may have been over-rated.
A number of combination chemotherapy schedules have been evaluated in the present work (Kopper & Steel, 1975; Nowak et al., 1978; Bailey et al., 1980b; ). There has not been space in this publication to review these studies in detail. However, they can be summarised in the statement that in no case was there statistically significant evidence for the growth delay of a drug combination exceeding the aggregate growth delays of the component single agents. Combination chemotherapy was usually effective in that a greater tumour response could be achieved within the toxicity limitations of the host than with any single agent, but this is to be attributed to nonoverlapping toxicity rather than to "synergistic" effects against tumour cells.
The assessment of therapeutic response in human tumour xenografts is not a simple matter. In situ measurements of response are vulnerable to artefacts from the substantial host response that appears to be mounted against grafts in immunosuppressed mice. This problem is not restricted to artificially immuno-suppressed mice for there is also evidence for such responses in nude mice (Sordat et al., 1982) . Further studies are under way in which (1982) *Average number of volume-doubling times saved by maximum tolerated dose treatment using the 3 single agents in common clinical use that were most effective in each category; data from this is being investigated, especially in response to local irradiation of the grafts. Clonogenic assays obviate the host response problem but as yet their application to a wide range of xenograft types has been limited by problems of tissue disaggregation and cell cloning. The main benefit of the clonogenic assay work has been in the study of the shape of cell survival curves. Drugs were chosen that gave a good response or were of clinical interest for the disease in question. For almost all of these cytotoxic agents the curves have been exponential, implying that the cellular sensitivity was relatively homogeneous within the tumours.
In view of the greater cost and technical limitations a programme on this scale could not have been mounted in nude mice and we are encouraged, in spite of the lack of stability of immune response in immuno-suppressed mice, to continue using them in studies of this type.
